Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Results of the Phase Ib/II trial of obinutuzumab-atezolizumab-lenalidomide for R/R FL

Nilanjan Ghosh MD, PhD, Levine Cancer Institute, Charlotte, NC, provides an overview of results of the final analysis of a Phase Ib/II trial of obinutuzumab-atezolizumab-lenalidomide for relapsed/refractory (R/R) follicular lymphoma. Dr Ghosh gives an overview of the study design and the observed safety profile. The 36-month progression-free survival rate was 68.4% and the overall survival rate was 90%. Achievement of measurable residual disease (MRD)-negativity was strongly associated with complete response. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Disclosures

Nilanjan Ghosh MD, PhD, has received personal fees for consulting or speakers bureau from AstraZeneca, Gilead/Kite, Janssen, Abbvie, Pharmacyclics, Genmab, Karyopharma, ADC Therapeutics, Adaptive Biotechnologies, Epizyme, Incyte, Bristol Myers Squibb and TG Therapeutics; and has received grant support from Genentech/Roche.